Final Five-Year Analysis of Phase 3 Data With ADSTILADRIN® (nadofaragene firadenovec-vncg) Shows Durable Bladder Preservation and Consistent Long-Term Safety in BCG-unresponsive NMIBC

Final Five-Year Analysis of Phase 3 Data With ADSTILADRIN® (nadofaragene firadenovec-vncg) Shows Durable Bladder Preservation and Consistent Long-Term Safety in BCG-unresponsive NMIBC

Business Wire

Published

PARSIPPANY, N.J.--(BUSINESS WIRE)--Final Five-Year Analysis of Phase 3 Data With ADSTILADRIN® Shows Durable Bladder Preservation & Consistent Long-Term Safety in BCG-unresponsive NMIBC

Full Article